Article
22 Jul 2026
Les schémas posologiques sont maintenus, mais la CSC confirme l’interdiction du Canada de breveter les méthodes de traitement médical
AUTHORS CONTENT
Article
21 Jul 2026
Dosing Regimens Survive But The SCC Keeps Canada’s Bar On Patenting Methods Of Medical Treatment
Article
19 May 2026
Health Canada Removes Phase III Trials For Biosimilars: What It Means For Patent Enforcement
Article
28 Apr 2026
Guerres De Frites : La CAF Confirme Une Interprétation Fondée Sur La Déférence Des Revendications De Brevets Dans McCain v. Simplot
Article
23 Apr 2026
French Fry Wars: FCA Affirms Deferential Claim Construction In McCain v. Simplot
Article
30 Mar 2026
Overbreadth Gets A Lifeguard: The FCA Blows The Whistle In ProSlide v. WhiteWater
Article
29 Dec 2025
Les lignes directrices définitives du CEPMB sur le prix des médicaments brevetés entrent en vigueur le 1er janvier 2026 : ce que cela signifie pour les entreprises pharmaceutiques innovantes
Article
23 Dec 2025
Final Patented Medicines Pricing Guidelines From The PMPRB Take Effect On January 1, 2026: What This Means For Innovative Pharma
Article
19 Dec 2025
Patent Infringement Damages Can Extend To Products Beyond Scope Of Claims
Article
21 Nov 2025
Dealing A New Hand: Federal Court Gives Card Game Patent A Second Chance
Article
06 Nov 2025
Streamlined Biosimilar Approvals: What The End Of Biosimilar Phase III Trials Means For Innovative Pharmaceutical Patent Holders
Article
28 Oct 2025
What The Frack? FCA Clarifies Claim Construction And Double Patenting
Article
04 Aug 2025
Aperçu du rapport statistique 2024-2025 de Santé Canada sur le régime canadien des brevets pharmaceutiques
Article
31 Jul 2025
Insights From Health Canada's 2024–2025 Statistical Report On Canadian Pharmaceutical Patent Regime
Article
20 Jun 2025
Biosimilar Update: Health Canada Reconsiders Requirement For Comparative Clinical Trials
Article
05 Jun 2025
Patent Re-Examination Board Decision Does Not Preclude Patent Validity Challenge In Court
Article
12 Feb 2025
Federal Court Re-balances Due Care Assessment For Reinstating Abandoned Patent Applications
Article
23 Dec 2024
Novel Biosimilar Anti-Trust Complaint Involving Janssen's STELARA (Ustekinumab) Dismissed By The Canadian Competition Tribunal
Article
19 Dec 2024
Federal Court Of Appeal: Patented Medicine Prices Review Board "Crashed" Through "Guardrails" In Attempt To Regulate Unpatented Medicine
Article
04 Oct 2024
The Diaper Wars, Episode 2: FCA Finds US Parent Company Liable For Patent Infringement